Parents Express Betrayal Over FDA's Limited Approval of Leucovorin for Autism Treatment

The FDA's recent decision to restrict the use of leucovorin, initially promoted as a treatment for autism, has left many parents feeling abandoned. Originally endorsed by the Trump administration, the FDA has now limited its approval to a rare genetic disorder, stating there is insufficient evidence for its effectiveness in treating autism. This shift has caused frustration among families who had high hopes for the medication, with some reporting difficulties in accessing it. Experts in autism have praised the FDA's decision as evidence-based, but the emotional impact on families is significant, as they continue to seek effective treatments for their children.

Key Details: • FDA's new approval limits leucovorin use to a rare genetic disorder. • Parents report feeling betrayed and frustrated by the FDA's decision. • Leucovorin prescriptions surged following initial endorsements but may decline now. • The cost of related testing is nearly $300 and is not covered by insurance. • Families are encouraged to consult with their healthcare providers regarding treatment options.